[
  {
    "ts": null,
    "headline": "Incyte Corp. stock underperforms Friday when compared to competitors",
    "summary": "Incyte Corp. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=bcbcd685a8a8c220ceaabdbfe387c13ec284a3b296b49f40e31c538696907394",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749834840,
      "headline": "Incyte Corp. stock underperforms Friday when compared to competitors",
      "id": 135404926,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=bcbcd685a8a8c220ceaabdbfe387c13ec284a3b296b49f40e31c538696907394"
    }
  },
  {
    "ts": null,
    "headline": "Specialised Therapeutics announces expanded partnership with Incyte",
    "summary": "Specialised Therapeutics announced the expansion of its existing supply and distribution agreement with Incyte (INCY) Biosciences International Sarl, the Swiss-based affiliate of Incyte, to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific region. The expanded agreement will see new therapies axatilimab and retifanlimab added to the current partnered portfolio of Minjuvi",
    "url": "https://finnhub.io/api/news?id=2b9e0a51ae2541455b1fbdb5ddcb4d4409b0b7e1bf65c81ae4460628d3160e8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749830709,
      "headline": "Specialised Therapeutics announces expanded partnership with Incyte",
      "id": 135258068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Specialised Therapeutics announced the expansion of its existing supply and distribution agreement with Incyte (INCY) Biosciences International Sarl, the Swiss-based affiliate of Incyte, to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific region. The expanded agreement will see new therapies axatilimab and retifanlimab added to the current partnered portfolio of Minjuvi",
      "url": "https://finnhub.io/api/news?id=2b9e0a51ae2541455b1fbdb5ddcb4d4409b0b7e1bf65c81ae4460628d3160e8c"
    }
  }
]